Published in Hematology Am Soc Hematol Educ Program on January 01, 2008
Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int J Cancer (2010) 1.23
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma (2009) 1.10
Pediatric, elderly, and emerging adult-onset peaks in Burkitt's lymphoma incidence diagnosed in four continents, excluding Africa. Am J Hematol (2012) 0.96
HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era. Adv Hematol (2011) 0.93
HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition. Clin Dev Immunol (2011) 0.85
Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition. Immunology (2014) 0.83
Orbital sporadic Burkitt lymphoma in an adult diabetic African American female and a review of adult orbital cases. Clin Ophthalmol (2011) 0.82
Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells. Oncotarget (2012) 0.81
MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas. Infect Agent Cancer (2013) 0.79
Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma. Chin J Cancer (2015) 0.78
The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells. Cancer Cell Int (2015) 0.78
Bilateral Numb Chin Syndrome as the Initial Presentation of Burkitt's Lymphoma/Leukemia: A Report of Two Cases and Review of the Literature. Case Rep Hematol (2016) 0.77
Xanthogranulomatous Appendicitis Mimicking Residual Burkitt's Lymphoma After Chemotherapy. Ann Coloproctol (2016) 0.75
Chemotherapy-Induced Perforation of Gastric Burkitt Lymphoma; A Case Report and Review of the Literature. Bull Emerg Trauma (2014) 0.75
Mature B cell neoplasms: retrospective analysis of 93 cases diagnosed between 2011 and 2014 in a University Hospital in southern Brazil. Rev Bras Hematol Hemoter (2016) 0.75
Intraoral Burkitt's lymphoma in an HIV positive patient. Indian J Sex Transm Dis (2012) 0.75
Molecular profiling of aggressive lymphomas. Adv Hematol (2011) 0.75
Expression of JL1 in Burkitt lymphoma is associated with improved overall survival. Virchows Arch (2011) 0.75
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med (2013) 4.49
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood (2013) 2.65
Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood (2002) 1.90
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol (2005) 1.78
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma (2012) 1.62
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol (2009) 1.57
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma (2011) 1.46
Breast lymphoma associated with breast implants: two case-reports and a review of the literature. Leuk Lymphoma (2002) 1.46
B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol (2006) 1.34
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol (2012) 1.17
Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab. Haematologica (2008) 1.16
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol (2008) 1.15
Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther (2011) 1.13
Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk (2010) 1.13
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma (2009) 1.10
Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol (2014) 1.10
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood (2012) 1.08
Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study. Ann Intern Med (2014) 1.05
Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Mol Cancer Ther (2012) 1.05
Vitamin D and non-Hodgkin lymphoma risk in adults: a review. Cancer Invest (2009) 1.00
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer (2011) 0.97
Symptomatic intracardiac diffuse large B-cell lymphoma. Am J Hematol (2009) 0.93
Salvage therapy in Hodgkin's lymphoma. Oncologist (2009) 0.91
Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience. Leuk Res (2005) 0.90
A case-control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults. Cancer Causes Control (2010) 0.90
Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest (2008) 0.90
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer (2013) 0.90
Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study. Cancer (2012) 0.89
Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys (2009) 0.87
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma (2014) 0.87
Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma. Haematologica (2006) 0.87
Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res (2011) 0.87
Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study. Cancer (2013) 0.87
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clin Cancer Res (2013) 0.86
Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy? Curr Hematol Malig Rep (2010) 0.83
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer (2014) 0.82
Management of marginal zone lymphoma. Oncology (Williston Park) (2013) 0.82
Monoclonal antibodies in lymphoma: the first decade. Semin Hematol (2008) 0.82
Rituximab for early-stage diffuse large-B-cell lymphoma. Lancet Oncol (2006) 0.81
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol (2013) 0.81
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. Leuk Lymphoma (2012) 0.80
The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer (2014) 0.80
Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. Oncology (Williston Park) (2007) 0.80
PCR assays detect B-lymphocyte clonality in formalin-fixed, paraffin-embedded specimens of classical hodgkin lymphoma without microdissection. Am J Clin Pathol (2010) 0.80
Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma. Haematologica (2008) 0.80
Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. Radiother Oncol (2012) 0.79
Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leuk Lymphoma (2014) 0.79
Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. Clin Immunol (2012) 0.79
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant (2010) 0.79
Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma (2004) 0.79
Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma. Semin Hematol (2008) 0.78
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Hematol Malig Rep (2008) 0.78
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer (2014) 0.78
Novel agents in mantle cell lymphoma. Best Pract Res Clin Haematol (2012) 0.77
Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era. Clin Cancer Res (2004) 0.77
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Clin Adv Hematol Oncol (2010) 0.76
Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma. Future Oncol (2015) 0.75
Relapsed/refractory diffuse large B-cell lymphoma: on the threshold of new therapies. Oncology (Williston Park) (2009) 0.75
Seeking wisdom from the Seer. Leuk Lymphoma (2009) 0.75
Getting to the heart of the problem in treating diffuse large B-cell lymphoma. Leuk Lymphoma (2011) 0.75
Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. Biol Blood Marrow Transplant (2011) 0.75
Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma. Curr Treat Options Oncol (2015) 0.75
Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys (2009) 0.75
Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Oncol Rep (2008) 0.75
Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. Am J Hematol (2011) 0.75
Accurate reporting of adverse events in chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol (2011) 0.75
Radioimmunotherapy for non-Hodgkin's lymphoma. Clin Cancer Res (2004) 0.75
Mantle cell lymphoma. Best Pract Res Clin Haematol (2012) 0.75
Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions. Oncology (Williston Park) (2017) 0.75
Combination treatment approaches and novel therapies for lymphoma. Clin Adv Hematol Oncol (2007) 0.75
Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma. Leuk Lymphoma (2014) 0.75